In the mid-1980s, MSD began its clinical HIV research in response to what the company perceived as a potential epidemic – our scientists were among the first to discover and develop medicines for the treatment of HIV.
Today, a future where HIV/AIDS can be a manageable illness is closer, in part, because of MSD’s response to the crisis.
Since the first HIV products became available nearly two decades ago, MSD has worked to expand access to our medicines, build healthcare infrastructure, and address health and development challenges around the world. MSD maintains longstanding efforts to deliver its medicines to those who need it most, including differential pricing, voluntary licensing, public-private partnerships, philanthropic programs, and continued research and development efforts in HIV.
WATCH THE VIDEO:
"TOGETHER FOR 30 YEARS AND COUNTING"
OUR FOUNDATION HAS CONTRIBUTED MORE THAN $122 MILLION OVER THE PAST 15 YEARS TO HELP ADDRESS BARRIERS TO HIV CARE ACROSS THE GLOBE,
WITH PROGRAMS FOCUSED IN BOTSWANA, CHINA AND THE U.S., INCLUDING:
for Underserved Populations in the U.S.: initiative launched to connect more people living with HIV to the care they need to stay healthy
(ACHAP): program established in 2000 with the Bill & Melinda Gates Foundation to support Botswana, a country disproportionately affected by HIV/AIDS
(C-MAP): a comprehensive AIDS initiative in China